RELEASED ON 06/02/13 (DD/MM/YY)
INVISTA and Arzeda have entered into an agreement to develop bio-based butadiene (BD) and other feedstock, the US-based companies said on Wednesday.
INVISTA produces adipic acid, which uses BD as a feedstock.
In the US, the advent of shale gas has encouraged several producers to crack light feeds instead of heavier naphtha. Lighter feeds produce much less crude C4, from which BD is extracted.
“As we seek innovative solutions to increase the global supply of butadiene, we believe developing a cost-competitive bio-derived route will help assure ample supply and reduce price volatility,” said Bill Greenfield, executive vice president of INVISTA’s nylon intermediates business, in a company statement.
Under the agreement, INVISTA and Arzeda will collaborate to develop each of their bio-based technologies with the ultimate goal of developing bio-based processes for several products, the companies said. The initial focus will be on bio-BD.
INVISTA already has capabilities and biotechnology and catalysis, the companies said. Arzeda designs enzymes.
SOURCE ICIS News - For internal use only
INVISTA and Arzeda have entered into an agreement to develop bio-based butadiene (BD) and other feedstock, the US-based companies said on Wednesday.
INVISTA produces adipic acid, which uses BD as a feedstock.
In the US, the advent of shale gas has encouraged several producers to crack light feeds instead of heavier naphtha. Lighter feeds produce much less crude C4, from which BD is extracted.
“As we seek innovative solutions to increase the global supply of butadiene, we believe developing a cost-competitive bio-derived route will help assure ample supply and reduce price volatility,” said Bill Greenfield, executive vice president of INVISTA’s nylon intermediates business, in a company statement.
Under the agreement, INVISTA and Arzeda will collaborate to develop each of their bio-based technologies with the ultimate goal of developing bio-based processes for several products, the companies said. The initial focus will be on bio-BD.
INVISTA already has capabilities and biotechnology and catalysis, the companies said. Arzeda designs enzymes.
SOURCE ICIS News - For internal use only